Cardiovascular Diseases: Semaglutide
2026-06-01 · Department of Health and Social Care · HL543 · Official question
Question
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 29 April (HL16182), whether they will publish the final NICE guidance for the use of semaglutide.
Answer
The National Institute for Health and Care Excellence published final technology appraisal guidance on the use of semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity on 7...